{"entity":{"id":"nct02487459","kind":"trial","name":"Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies","aka":[],"tldr":"A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, withdrawn before enrolling.","summary":"Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies is a phase 1 interventional study registered as NCT02487459 by Bellicum Pharmaceuticals, started 2016-07. Conditions recorded: Hematologic Malignancies. Interventions recorded: BPX-501 and AP1903.","status":"withdrawn","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02487459","url":"https://clinicaltrials.gov/study/NCT02487459"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["rivogenlecleucel"],"companies":["bellicum"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02487459","phase":"1","setting":"A Phase I/II Safety Study of Planned BPX-501 T Cell Infusion After Partially Mismatched, Related, HSCT in Adults With Advanced Hematologic Malignances at High Risk for Relapse","sponsor":"Bellicum Pharmaceuticals","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02487459/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"rivogenlecleucel","kind":"drug","name":"Rivogenlecleucel","route":"/drugs/rivogenlecleucel/"}],"company":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/"}]}}